Shares of Bellicum Pharmacueticals Inc. (NASDAQ:BLCM) saw unusually-high trading volume on Friday . Approximately 416,429 shares were traded during mid-day trading, an increase of 0% from the previous session’s volume of 414,646 shares.The stock last traded at $15.27 and had previously closed at $14.71.

BLCM has been the subject of a number of research reports. Zacks Investment Research downgraded shares of Bellicum Pharmacueticals from a “hold” rating to a “sell” rating in a research note on Thursday, March 17th. Piper Jaffray Cos. reaffirmed a “buy” rating and set a $33.00 target price (down previously from $45.00) on shares of Bellicum Pharmacueticals in a research note on Monday, March 14th. SunTrust Banks Inc. started coverage on shares of Bellicum Pharmacueticals in a research note on Thursday, June 2nd. They set a “buy” rating and a $20.00 target price for the company. Finally, Jefferies Group decreased their target price on shares of Bellicum Pharmacueticals from $35.00 to $19.00 and set a “buy” rating for the company in a research note on Tuesday, March 15th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $28.00.

The stock’s market capitalization is $403.68 million. The company has a 50-day moving average price of $12.37 and a 200-day moving average price of $11.63.

Bellicum Pharmacueticals (NASDAQ:BLCM) last announced its quarterly earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.51) by $0.07. Equities analysts predict that Bellicum Pharmacueticals Inc. will post ($2.22) earnings per share for the current year.

In other Bellicum Pharmacueticals news, VP Ken Moseley sold 15,000 shares of the company’s stock in a transaction on Thursday, June 2nd. The shares were sold at an average price of $13.00, for a total transaction of $195,000.00. Following the completion of the transaction, the vice president now directly owns 15,196 shares in the company, valued at $197,548. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CTO Kevin M. Slawin sold 55,000 shares of the company’s stock in a transaction on Friday, April 22nd. The stock was sold at an average price of $11.43, for a total transaction of $628,650.00. Following the transaction, the chief technology officer now owns 159,206 shares of the company’s stock, valued at $1,819,724.58. The disclosure for this sale can be found here.

A hedge fund recently raised its stake in Bellicum Pharmacueticals stock. Morgan Stanley raised its position in shares of Bellicum Pharmacueticals Inc. (NASDAQ:BLCM) by 21.1% during the fourth quarter, Holdings Channel reports. The firm owned 426,861 shares of the biopharmaceutical company’s stock after buying an additional 74,454 shares during the period. Morgan Stanley owned 1.61% of Bellicum Pharmacueticals worth $8,653,000 at the end of the most recent reporting period.

Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company is using its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system in real time.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.